On July 9, the US Food and Drug Administration approved the supplemental new drug application for roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis (AD) in adults and in pediatric patients aged 6 years or older. Roflumilast cream 0.15%, which has been developed by Arcutis Biotherapeutics and is marketed under the ...
.png)
 Copyright © 2023 googlenewsandentertainment. All Rights Reserved
